GILEAD SCIENCES, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
GILEAD SCIENCES, INC. (GILD) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $106.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-24
- GILEAD SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $32.00M.
- GILEAD SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-09-30 was $181.00M.
- GILEAD SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-06-30 was $70.00M.
- GILEAD SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-03-31 was $30.00M.
- GILEAD SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $106.00M, a 23.26% increase from fiscal 2024.
- GILEAD SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $86.00M, a 59.81% decline from fiscal 2023.
- GILEAD SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $214.00M, a 120.62% increase from fiscal 2022.
- GILEAD SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $97.00M, a 10.23% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $106.00M 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $86.00M 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $214.00M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $97.00M 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $88.00M 10-K · filed 2023-02-22 | |||
| 2020-12-31 | $88.00M 10-K · filed 2022-02-23 | |||
| 2019-12-31 | $32.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $213.00M derived: sum of 2 quarters · filed 2021-02-25 | $283.00M derived: sum of 3 quarters · filed 2021-02-25 | $313.00M 10-K · filed 2021-02-25 |
| 2019-09-30 | $181.00M 10-Q · filed 2019-11-05 | $251.00M derived: sum of 2 quarters · filed 2019-11-05 | $281.00M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $70.00M 10-Q · filed 2019-08-06 | $100.00M 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $30.00M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |